Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene

J Thorac Oncol. 2015 Sep;10(9):e95-e96. doi: 10.1097/JTO.0000000000000611.

Authors

Hsu Wu¹, Jin-Yuan Shih², James Chih-Hsin Yang³

Affiliations

¹ Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
² Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
³ Graduate Institute of Oncology, National Taiwan University and, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Electronic address: [email protected].

PMID: 26291023
DOI: 10.1097/JTO.0000000000000611

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma of Lung
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
Female
Humans
Indoles / administration & dosage
Indoles / therapeutic use*
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Middle Aged
Oncogene Proteins, Fusion / genetics*
Oncogene Proteins, Fusion / metabolism*
Pyrroles / administration & dosage
Pyrroles / therapeutic use*
Sunitinib

Substances

Antineoplastic Agents
Indoles
KIF5B-RET fusion protein, human
Oncogene Proteins, Fusion
Pyrroles
Sunitinib

Associated data

ClinicalTrials.gov/NCT01639508
ClinicalTrials.gov/NCT01813734
ClinicalTrials.gov/NCT01823068
ClinicalTrials.gov/NCT01829217
ClinicalTrials.gov/NCT01877083